Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trientine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.92 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 5/20 | 0.92 |
| ▸ | CA6 | P23280 | 5/20 | 0.92 |
| ▸ | CA7 | P43166 | 5/20 | 0.92 |
| ▸ | CA9 | Q16790 | 5/20 | 0.92 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.92 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.92 |
| ▸ | CA4 | P22748 | 4/20 | 0.92 |
| ▸ | CA5A | P35218 | 4/20 | 0.92 |
| ▸ | LMNA | P02545 | 3/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.92 |
| ▸ | CA3 | P07451 | 3/20 | 0.92 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.92 |
| ▸ | CA1 | P00915 | 2/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.92 |
| ▸ | TP53 | P04637 | 1/20 | 0.92 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | RECQL | P46063 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28797750 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL285388 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL284758 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Trientine SCHEMBL2027642 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Trientine SCHEMBL205201 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Trientine SCHEMBL505712 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Trientine SCHEMBL506189 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL1625351 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL1626082 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 | |
| Hydrochloric Acid SCHEMBL28797761 | 1.00 | KDM4E (1.00) | KDM4ECA12CA6CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110448994-B | Process method for trapping NO by using renewable amino functional eutectic solvent | 北京化工大学 | 2022-08-05 | — | — | CN | claimed |
| US-11795150-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2023-10-24 | — | — | US | disclosed |
| CN-112055712-B | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-110448994-B | Process method for trapping NO by using renewable amino functional eutectic solvent | 北京化工大学 | 2022-08-05 | — | — | CN | disclosed |
| US-20200148647-A1 | Synthesis of Triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2020-05-14 | — | — | US | disclosed |
| US-20170226064-A1 | Synthesis of Triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2017-08-10 | — | — | US | disclosed |
| US-9556123-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2017-01-31 | — | — | US | disclosed |
| US-20160102060-A1 | Synthesis of Triethylenetetramines | PROTEMIX CORPORATION LIMITED (NZ) | 2016-04-14 | — | — | US | disclosed |
| US-20150057466-A1 | Synthesis of Triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2015-02-26 | — | — | US | disclosed |
| US-8912362-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2014-12-16 | — | — | US | disclosed |
| US-8067641-B2 | Synthesis of triethylenetetramines | PHILERA NEW ZEALAND LIMITED (NZ) | 2011-11-29 | — | — | US | disclosed |
| US-20100173994-A1 | Synthesis of triethylenetetramines | PROTEMIX CORPORATION LIMITED (NZ) | 2010-07-08 | — | — | US | disclosed |
| US-7582796-B2 | starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride | PROTEMIX CORPORATION LIMITED (NZ) | 2009-09-01 | — | — | US | disclosed |
| EP-1778618-A4 | SYNTHESIS OF TRIETHYLENETETRAMINES | PROTEMIX CORP LTD (NZ) | 2008-07-16 | — | — | EP | disclosed |
| EP-1778618-A2 | SYNTHESIS OF TRIETHYLENETETRAMINES | Protemix Corporation Limited (NZ) | 2007-05-02 | — | — | EP | disclosed |
| EP-1694317-A1 | COPPER ANTAGONIST COMPOUNDS | Protemix Corporation Limited (NZ) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006027705-A2 | SYNTHESIS OF TRIETHYLENETETRAMINES | PROTEMIX CORPORATION LIMITED (NZ) | 2006-03-16 | — | — | WO | disclosed |
| US-20060041170-A1 | starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride | PHILERA NEW ZEALAND LIMITED (NZ) | 2006-02-23 | — | — | US | disclosed |
| US-20050159364-A1 | Copper antagonist compounds | PROTEMIX CORPORATION LIMITED (NZ) | 2005-07-21 | — | — | US | disclosed |
| WO-2005058294-A1 | COPPER ANTAGONIST COMPOUNDS | PROTEMIX CORPORATION LIMITED (NZ) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795150-B2 | Synthesis of triethylenetetramines | PNMT, TES, TPR | CA2 4784/4885ESR1 910/4885KDM4E 1025/4885 |
| US-20160102060-A1 | Synthesis of Triethylenetetramines | PNMT, TES, TPR | CA2 4784/4885ESR1 910/4885KDM4E 1025/4885 |
| US-20170226064-A1 | Synthesis of Triethylenetetramines | PNMT, TES, TPR | CA2 4784/4885ESR1 910/4885KDM4E 1025/4885 |
| US-20050159364-A1 | Copper antagonist compounds | SOD1, CLN6, SOD3 | CA2 1853/4885ESR1 3090/4885KDM4E 4129/4885 |
| US-20150057466-A1 | Synthesis of Triethylenetetramines | PNMT, TES, TPR | CA2 4784/4885ESR1 910/4885KDM4E 1025/4885 |
| US-20200148647-A1 | Synthesis of Triethylenetetramines | PNMT, TES, TPR | CA2 4784/4885ESR1 910/4885KDM4E 1025/4885 |
| US-20060041170-A1 | starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride | TET1, TET2, TET3 | CA2 2607/4885ESR1 1845/4885KDM4E 248/4885 |
| US-20100173994-A1 | Synthesis of triethylenetetramines | PNMT, TES, TPR | CA2 4784/4885ESR1 910/4885KDM4E 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.